EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.
Age ≥18 years [+6]
Use of (neo-)adjuvant androgen deprivation therapy [+6]